Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Datopotamab deruxtecan versus docetaxel in previously treated TROP2-positive advanced or metastatic non-squamous NSCLC without actionable driver alterations
CTR20254226Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of datopotamab deruxtecan, docetaxel in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Dec 2025; status: active.
02
Drugs
datopotamab deruxtecandocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20254226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254226.